Large Molecule Drug Substance CDMO Market Size, Share, Growth, and Industry Analysis, By Type (Contract Manufacturing, Contract Development), By Application (Biotech Companies, CRO, Others), Regional Insights and Forecast to 2035

Table of Content

1 Market Overview
1.1 Product Definition and Market Characteristics
1.2 Global Large Molecule Drug Substance CDMO Market Size
1.3 Market Segmentation
1.4 Regulatory Environment

2 Industry Chain Analysis
2.1 Industry Chain Analysis
2.2 Large Molecule Drug Substance CDMO Raw Materials Analysis
2.2.1 Key Raw Materials Introduction
2.2.2 Key Suppliers of Raw Materials
2.3 Large Molecule Drug Substance CDMO Business Mode and Production Process
2.3.1 Large Molecule Drug Substance CDMO Business Mode Analysis
2.3.2 Production Process Analysis
2.4 Large Molecule Drug Substance CDMO Cost Structure Analysis
2.4.1 Manufacturing Cost Structure of Large Molecule Drug Substance CDMO
2.4.2 Raw Material Cost of Large Molecule Drug Substance CDMO
2.4.3 Labor Cost of Large Molecule Drug Substance CDMO
2.5 Market Channel Analysis
2.6 Major Downstream Customers Analysis
2.7 Alternative Product Analysis

3 Market Dynamics
3.1 Market Drivers
3.2 Market Constraints and Challenges
3.3 Emerging Market Trends
3.4 PESTEL Analysis
3.5 Consumer Insights Analysis
3.6 Impact of Russia and Ukraine War

4 Market Competitive Landscape
4.1 Global Large Molecule Drug Substance CDMO Revenue and Market Share by Manufacturer (2021-2026)
4.2 Global Large Molecule Drug Substance CDMO Sales Volume and Market Share by Manufacturer (2021-2026)
4.3 Global Large Molecule Drug Substance CDMO Price by Manufacturer (2021-2026)
4.4 Large Molecule Drug Substance CDMO Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
4.5 Global Key Manufacturers of Large Molecule Drug Substance CDMO, Manufacturing Base Distribution and Headquarters
4.6 Global Key Manufacturers of Large Molecule Drug Substance CDMO, Product Offered and Application
4.7 Large Molecule Drug Substance CDMO Market Competitive Situation and Trends
4.7.1 Large Molecule Drug Substance CDMO Market Concentration Rate
4.7.2 Global Top 3 and Top 6 Large Molecule Drug Substance CDMO Players Market Share by Revenue
4.8 Industry News
4.8.1 Key Product Launch News
4.8.2 Mergers & Acquisitions, Expansion Plans

5 Global Large Molecule Drug Substance CDMO Market Historical Development by Geographic Region (2021-2026)
5.1 Global Large Molecule Drug Substance CDMO Market Historical Sales Volume by Geographic Region (2021-2026)
5.2 Global Large Molecule Drug Substance CDMO Market Historical Revenue by Geographic Region (2021-2026)
5.3 North America Large Molecule Drug Substance CDMO Market Status by Country (2021-2026)
5.3.1 North America Large Molecule Drug Substance CDMO Sales Volume by Country (2021-2026)
5.3.2 North America Large Molecule Drug Substance CDMO Revenue by Country (2021-2026)
5.3.3 United States Large Molecule Drug Substance CDMO Sales Volume, Revenue and Growth (2021-2026)
5.3.4 Canada Large Molecule Drug Substance CDMO Sales Volume, Revenue and Growth (2021-2026)
5.4 Europe Large Molecule Drug Substance CDMO Market Status by Country (2021-2026)
5.4.1 Europe Large Molecule Drug Substance CDMO Sales Volume by Country (2021-2026)
5.4.2 Europe Large Molecule Drug Substance CDMO Revenue by Country (2021-2026)
5.4.3 Germany Large Molecule Drug Substance CDMO Sales Volume, Revenue and Growth (2021-2026)
5.4.4 France Large Molecule Drug Substance CDMO Sales Volume, Revenue and Growth (2021-2026)
5.4.5 United Kingdom Large Molecule Drug Substance CDMO Sales Volume, Revenue and Growth (2021-2026)
5.4.6 Spain Large Molecule Drug Substance CDMO Sales Volume, Revenue and Growth (2021-2026)
5.4.7 Russia Large Molecule Drug Substance CDMO Sales Volume, Revenue and Growth (2021-2026)
5.4.8 Poland Large Molecule Drug Substance CDMO Sales Volume, Revenue and Growth (2021-2026)
5.5 Asia Pacific Large Molecule Drug Substance CDMO Market Status by Country (2021-2026)
5.5.1 Asia Pacific Large Molecule Drug Substance CDMO Sales Volume by Country (2021-2026)
5.5.2 Asia Pacific Large Molecule Drug Substance CDMO Revenue by Country (2021-2026)
5.5.3 China Large Molecule Drug Substance CDMO Sales Volume, Revenue and Growth (2021-2026)
5.5.4 Japan Large Molecule Drug Substance CDMO Sales Volume, Revenue and Growth (2021-2026)
5.5.5 South Korea Large Molecule Drug Substance CDMO Sales Volume, Revenue and Growth (2021-2026)
5.5.6 Southeast Asia Large Molecule Drug Substance CDMO Sales Volume, Revenue and Growth (2021-2026)
5.5.7 India Large Molecule Drug Substance CDMO Sales Volume, Revenue and Growth (2021-2026)
5.5.8 Australia Large Molecule Drug Substance CDMO Sales Volume, Revenue and Growth (2021-2026)
5.6 Latin America Large Molecule Drug Substance CDMO Market Status by Country (2021-2026)
5.6.1 Latin America Large Molecule Drug Substance CDMO Sales Volume by Country (2021-2026)
5.6.2 Latin America Large Molecule Drug Substance CDMO Revenue by Country (2021-2026)
5.6.3 Mexico Large Molecule Drug Substance CDMO Sales Volume, Revenue and Growth (2021-2026)
5.6.4 Brazil Large Molecule Drug Substance CDMO Sales Volume, Revenue and Growth (2021-2026)
5.7 Middle East and Africa Large Molecule Drug Substance CDMO Market Status by Country (2021-2026)
5.7.1 Middle East and Africa Large Molecule Drug Substance CDMO Sales Volume by Country (2021-2026)
5.7.2 Middle East and Africa Large Molecule Drug Substance CDMO Revenue by Country (2021-2026)
5.7.3 GCC Large Molecule Drug Substance CDMO Sales Volume, Revenue and Growth (2021-2026)
5.7.4 South Africa Large Molecule Drug Substance CDMO Sales Volume, Revenue and Growth (2021-2026)

6 Global Large Molecule Drug Substance CDMO Market Historical Development by Product Type (2021-2026)
6.1 Large Molecule Drug Substance CDMO Definition by Type
6.2 Global Large Molecule Drug Substance CDMO Historical Sales Volume by Product Type (2021-2026)
6.3 Global Large Molecule Drug Substance CDMO Historical Revenue by Product Type (2021-2026)
6.4 Global Large Molecule Drug Substance CDMO Historical Price by Product Type (2021-2026)
6.5 Global Historical Sales Volume, Revenue and Growth Rate by Product Type (2021-2026)
6.5.1 Global Large Molecule Drug Substance CDMO Historical Sales Volume, Revenue and Growth Rate of Contract Manufacturing (2021-2026)
6.5.2 Global Large Molecule Drug Substance CDMO Historical Sales Volume, Revenue and Growth Rate of Contract Development (2021-2026)

7 Global Large Molecule Drug Substance CDMO Market Historical Development by End User (2021-2026)
7.1 Downstream Market Overview
7.2 Global Large Molecule Drug Substance CDMO Historical Sales Volume by End User (2021-2026)
7.3 Global Large Molecule Drug Substance CDMO Historical Revenue by End User (2021-2026)
7.4 Global Large Molecule Drug Substance CDMO Historical Price by End User (2021-2026)
7.5 Global Historical Sales Volume, Revenue and Growth Rate by End User (2021-2026)
7.5.1 Global Large Molecule Drug Substance CDMO Historical Sales Volume, Revenue and Growth Rate of Biotech Companies (2021-2026)
7.5.2 Global Large Molecule Drug Substance CDMO Historical Sales Volume, Revenue and Growth Rate of CRO (2021-2026)
7.5.3 Global Large Molecule Drug Substance CDMO Historical Sales Volume, Revenue and Growth Rate of Others (2021-2026)

8 Leading Companies Profiles
8.1 WuXi Biologics
8.1.1 WuXi Biologics Corporation Information
8.1.2 WuXi Biologics - Large Molecule Drug Substance CDMO Product Portfolio and Specification
8.1.3 WuXi Biologics Performance Analysis (2021-2026)
8.1.4 WuXi Biologics Business and Markets Served
8.1.5 WuXi Biologics Recent Developments
8.2 AGC Biologics
8.2.1 AGC Biologics Corporation Information
8.2.2 AGC Biologics - Large Molecule Drug Substance CDMO Product Portfolio and Specification
8.2.3 AGC Biologics Performance Analysis (2021-2026)
8.2.4 AGC Biologics Business and Markets Served
8.2.5 AGC Biologics Recent Developments
8.3 Eurofins Scientific
8.3.1 Eurofins Scientific Corporation Information
8.3.2 Eurofins Scientific - Large Molecule Drug Substance CDMO Product Portfolio and Specification
8.3.3 Eurofins Scientific Performance Analysis (2021-2026)
8.3.4 Eurofins Scientific Business and Markets Served
8.3.5 Eurofins Scientific Recent Developments
8.4 Samsung Biologics
8.4.1 Samsung Biologics Corporation Information
8.4.2 Samsung Biologics - Large Molecule Drug Substance CDMO Product Portfolio and Specification
8.4.3 Samsung Biologics Performance Analysis (2021-2026)
8.4.4 Samsung Biologics Business and Markets Served
8.4.5 Samsung Biologics Recent Developments
8.5 LabCorp Drug Development, and FUJIFILM Diosynth Biotechnologies
8.5.1 LabCorp Drug Development, and FUJIFILM Diosynth Biotechnologies Corporation Information
8.5.2 LabCorp Drug Development, and FUJIFILM Diosynth Biotechnologies - Large Molecule Drug Substance CDMO Product Portfolio and Specification
8.5.3 LabCorp Drug Development, and FUJIFILM Diosynth Biotechnologies Performance Analysis (2021-2026)
8.5.4 LabCorp Drug Development, and FUJIFILM Diosynth Biotechnologies Business and Markets Served
8.5.5 LabCorp Drug Development, and FUJIFILM Diosynth Biotechnologies Recent Developments
8.6 Recipharm AB (publ)
8.6.1 Recipharm AB (publ) Corporation Information
8.6.2 Recipharm AB (publ) - Large Molecule Drug Substance CDMO Product Portfolio and Specification
8.6.3 Recipharm AB (publ) Performance Analysis (2021-2026)
8.6.4 Recipharm AB (publ) Business and Markets Served
8.6.5 Recipharm AB (publ) Recent Developments
8.7 Siegfried Holding AG
8.7.1 Siegfried Holding AG Corporation Information
8.7.2 Siegfried Holding AG - Large Molecule Drug Substance CDMO Product Portfolio and Specification
8.7.3 Siegfried Holding AG Performance Analysis (2021-2026)
8.7.4 Siegfried Holding AG Business and Markets Served
8.7.5 Siegfried Holding AG Recent Developments
8.8 Cambrex Corp.
8.8.1 Cambrex Corp. Corporation Information
8.8.2 Cambrex Corp. - Large Molecule Drug Substance CDMO Product Portfolio and Specification
8.8.3 Cambrex Corp. Performance Analysis (2021-2026)
8.8.4 Cambrex Corp. Business and Markets Served
8.8.5 Cambrex Corp. Recent Developments
8.9 Catalent, Inc.
8.9.1 Catalent, Inc. Corporation Information
8.9.2 Catalent, Inc. - Large Molecule Drug Substance CDMO Product Portfolio and Specification
8.9.3 Catalent, Inc. Performance Analysis (2021-2026)
8.9.4 Catalent, Inc. Business and Markets Served
8.9.5 Catalent, Inc. Recent Developments

9 Global Large Molecule Drug Substance CDMO Market Forecast by Product Type and End User (2026-2034)
9.1 Global Large Molecule Drug Substance CDMO Market Forecast by Product Type (2026-2034)
9.1.1 Global Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth Rate of Contract Manufacturing (2026-2034)
9.1.2 Global Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth Rate of Contract Development (2026-2034)
9.2 Global Large Molecule Drug Substance CDMO Market Forecast by End User (2026-2034)
9.2.1 Global Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth Rate of Biotech Companies (2026-2034)
9.2.2 Global Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth Rate of CRO (2026-2034)
9.2.3 Global Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth Rate of Others (2026-2034)

10 Global Large Molecule Drug Substance CDMO Market Forecast by Geographic Region (2026-2034)
10.1 Global Large Molecule Drug Substance CDMO Sales Volume and Revenue Forecast by Geographic Region (2026-2034)
10.2 North America Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.2.1 United States Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.2.2 Canada Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.3 Europe Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.3.1 Germany Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.3.2 France Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.3.3 United Kingdom Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.3.4 Spain Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.3.5 Russia Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.3.6 Poland Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.4 Asia Pacific Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.4.1 China Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.4.2 Japan Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.4.3 South Korea Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.4.4 Southeast Asia Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.4.5 India Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.4.6 Australia Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.5 Latin America Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.5.1 Mexico Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.5.2 Brazil Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.6 Middle East and Africa Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.6.1 GCC Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)
10.6.2 South Africa Large Molecule Drug Substance CDMO Sales Volume, Revenue Forecast and Growth (2026-2034)

11 Appendix
11.1 Methodology
11.2 Research Data Source
11.2.1 Secondary Data
11.2.2 Primary Data
11.2.3 Market Size Estimation
11.2.4 Legal Disclaimer